

What is Bronchiolitis Obliterans Syndrome?

Bronchiolitis Obliterans Syndrome (BOS) was first described **in the 1950's**¹


It is often associated with lung transplant and allogeneic hematopoietic stem cell transplant

There is **no approved therapy**



BOS is a **life-threatening disease**

WHERE the immune system **attacks** the **small airways** of the lungs causing **obstruction** of the airways



Affects an estimated **30,000 people** worldwide³



BOS has really been the **Achilles heel** of lung transplantation.

It's the leading cause of death beyond the first year after transplantation.



Ramsey Hachem, MD, Washington University in St. Louis and Barnes-Jewish Hospital



BOS affects **Adults and Children**⁴



¹ Gourtsoyiannis, NC. Radiologic-Pathologic Correlations from Head to Toe. 2005: p.154
² Chambers DC, et al. J Heart Lung Transplant. 2018;37:1169-1183

³ Data on File, Breath Therapeutics, a Zambon company, 2019.
⁴ Benden C. Pediatric Lung Transplantation. J Thorac Dis. 2017


What is Liposomal Cyclosporine A for Inhalation (L-CsA-i*)?

Cyclosporine is a **well known immunosuppressive** drug


L-CsA-i is a liposomal formulation of **cyclosporine A** developed for **inhalation use**



We combined L-CsA-i with an investigational customized **nebulizer**. Designed for **home inhalation**



The rationale of inhaled therapies:
Deliver drug directly to the lungs
WITH lower systemic exposure



BOSTON **PROGRAM**

Breath's clinical program with 5 clinical trials

is evaluating **L-CsA-i** as a **first potential therapy for BOS.**

* L-CsA-i is an investigational drug and its safety and efficacy have not been established